Skip to Content

Our Science

What is CRISPR?

Intellia is currently investigating the use of CRISPR gene editing technology to potentially treat genetic diseases. CRISPR, an acronym for Clustered Regularly Interspaced Short Palindromic Repeats, is a gene editing tool adapted from a naturally occurring bacterial immune system. It allows scientists to harness the power of natural DNA repair mechanisms to make targeted changes to the genome — the complete set of genetic instructions found in a cell.

Gene editing refers to a set of technologies, including CRISPR, that can be used to modify DNA sequences inside living cells. These modifications can be made to cells inside the body (in vivo) or to cells removed from the body, such as from a patient or donor, and then reintroduced (ex vivo).

In the future, Intellia hopes to use its CRISPR technology to treat a variety of diseases.

Types of Edits

Genetically driven diseases, caused by mutations (a change in the DNA sequence), come in many different forms. Intellia is applying and optimizing its CRISPR gene editing platform to address each of these types of mutations.

In Vivo

CRISPR is the therapy

Our systemic lipid nanoparticle (LNP)-based delivery system has unlocked treatment of genetic diseases to both selectively knock out disease-causing genes and restore necessary genetic functions by targeted insertion.

Ex Vivo

CRISPR creates the therapy

We are focused on engineering T cell therapies to provide them with particular enhanced attributes that may enable them to more effectively treat oncological and immunological diseases. Our approach is designed to improve safety and efficacy by engineering cell therapies that are more precise, potent and persistent.

CRISPR Videos

How CRISPR/Cas9 Works

Genetics and CRISPR: 101

How Intellia's In Vivo Approach Works

How Intellia's Ex Vivo Approach Works

Intellia's Investigational ATTR Program

Intellia's Investigational HAE Program